Sep 27, 2021 8:30 am EDT European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
Sep 03, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Sep 02, 2021 8:30 am EDT Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
Aug 09, 2021 4:02 pm EDT Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
Aug 09, 2021 4:01 pm EDT Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
Aug 02, 2021 6:00 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 02, 2021 8:30 am EDT Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
Jul 02, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jul 01, 2021 4:30 pm EDT Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
Jun 07, 2021 10:30 am EDT Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect